Articles

Fundstrat’s Tom Lee said he thinks U.S. stocks will experience a 7% to 10% drawdown over the next two months — a ‘buy the dip’ opportunity for investors. 

The alcoholic-beverages maker plans to take a goodwill impairment loss in its wine and spirits business of up to $2.5 billion.

Futures contracts for the S&P 500 have become more sensitive to U.S. jobs reports than inflation readings, according to BofA Global Research. 

The U.S. large-cap benchmark stock index is heavily concentrated on a handful of stocks. There is an easy way to broaden your risk — one that has performed better over the years.

Boeing’s stock took a beating Tuesday, after Wells Fargo warned investors to get out, as whatever decision the troubled aerospace giant makes on what to do with its cash and debt will likely be bad for the stock.

Summer’s over and the stock market’s most troublesome month is under way. But looking beyond September — and October, for that matter — the historical data are more encouraging.

Starliner is slated to return to Earth empty, while its crew will stay on the International Space Station for a few more months.

Construction spending fell 0.3% in July, the Commerce Department reported Tuesday.

Shares are among leading S&P 500 gainers early in Tuesday action as Super Micro looks to reassure customers

A key barometer of U.S. factories was negative for the fifth straight month, signaling the manufacturing side of the economy is still in a deep slump that might not end until after the presidential election.

The Phase 2 trial was evaluating the vaccine called VLA15 following a second booster dose given one year after the first one.

Vaxcyte Inc.’s stock soared 42% Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 and older.